Premium
Reduction in microalbuminuria in diabetics by eicosapentaenoic acid ethyl ester
Author(s) -
Hamazaki Tomohito,
Takazakura Eisuke,
Osawa Kenzo,
Urakaze Masaharu,
Yano Saburo
Publication year - 1990
Publication title -
lipids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 120
eISSN - 1558-9307
pISSN - 0024-4201
DOI - 10.1007/bf02537161
Subject(s) - medicine , endocrinology , microalbuminuria , creatinine , eicosapentaenoic acid , blood urea nitrogen , chemistry , insulin , urine , urea , blood pressure , fatty acid , polyunsaturated fatty acid , biochemistry
Eicosapentaenoic acid (EPA) ethyl ester (1.8 g/d) was administered to 16 diabetic patients (5 insulin‐dependent and 11 noninsulin‐dependent diabetics) for 6 mon. EPA in total plasma fatty acids increased from 4.0±2.4 mol% (mean±SD) to 7.5±3.1 mol% (p<0.001). Albumin excretion, measured with spot urine, was significantly reduced from 65 to 36 mg/g creatinine (geometric means, p<0.001). Fasting blood sugar levels, glycohemoglobin, body weight and blood pressure did not change significantly during the study. There were also no significant changes in serum levels of creatinine, urea nitrogen, total cholesterol and triglycerides. Although no overt hemorrhage was observed in the patients, hematocrit was reduced from 42.6±2.8% to 41.0±3.9% (p<0.02). Ten other similar diabetic patients (4 insulin‐dependent and 6 non‐insulin‐dependent diabetics) were followed as a reference group, not concomitantly, for 6 mon with neither EPA ethyl ester nor placebo. The parameters mentioned above were not changed significantly in this group during 6 mon. EPA administration might retard the appearance of overt diabetic nephropathy.